Gennaio 2023 - Nouscom

Nouscom announces appointment of Yen-Ching Chua as Vice President of Clinical Operations

We are thrilled to welcome Yen-Ching Chua as VP of Clinical Operations at Nouscom. Yen-Ching is an experienced global clinical operations leader with over 20 years expertise in leading [...]

Nouscom Announces Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate NOUS-209 in combination with KEYTRUDA® (pembrolizumab) in a Phase 2 Randomized Trials in dMMR/MSI-High Metastatic Colorectal Cancer

BASEL, Switzerland – 5th January 2023 – Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized immunotherapies, today announced that it has entered into [...]

error: Content is protected !!!